<SEC-DOCUMENT>0002012383-25-000642.txt : 20250204
<SEC-HEADER>0002012383-25-000642.hdr.sgml : 20250204
<ACCEPTANCE-DATETIME>20250204154544
ACCESSION NUMBER:		0002012383-25-000642
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250204

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Monte Rosa Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001826457
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92649
		FILM NUMBER:		25587840

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		617-949-2643

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BlackRock, Inc.
		CENTRAL INDEX KEY:			0002012383
		STANDARD INDUSTRIAL CLASSIFICATION:	SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211]
		ORGANIZATION NAME:           	02 Finance
		IRS NUMBER:				991116001
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		50 HUDSON YARDS
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		(212) 810-5800

	MAIL ADDRESS:	
		STREET 1:		50 HUDSON YARDS
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BlackRock Funding, Inc. /DE
		DATE OF NAME CHANGE:	20240215
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
                <submissionType>SCHEDULE 13G</submissionType>
        <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0002012383</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
            <liveTestFlag>LIVE</liveTestFlag>


        </filerInfo>
    </headerData>
    <formData>
        <coverPageHeader>
            <securitiesClassTitle>Common Stock</securitiesClassTitle>

            <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
            <issuerInfo>
                <issuerCik>0001826457</issuerCik>
                <issuerName>Monte Rosa Therapeutics, Inc.</issuerName>
                <issuerCusip>61225M102</issuerCusip>
                <issuerPrincipalExecutiveOfficeAddress>
                    <com:street1>321 HARRISON AVENUESUITE 900</com:street1>
                    <com:city>BOSTON</com:city>
                    <com:stateOrCountry>MA</com:stateOrCountry>
                    <com:zipCode>02118</com:zipCode>
                </issuerPrincipalExecutiveOfficeAddress>
            </issuerInfo>
            <designateRulesPursuantThisScheduleFiled>
                <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
            </designateRulesPursuantThisScheduleFiled>
        </coverPageHeader>
        <coverPageHeaderReportingPersonDetails>

            <reportingPersonName>BlackRock, Inc.</reportingPersonName>
            <memberGroup>b</memberGroup>
            <citizenshipOrOrganization>DE</citizenshipOrOrganization>
            <reportingPersonBeneficiallyOwnedNumberOfShares>
                <soleVotingPower>3782397</soleVotingPower>
                <sharedVotingPower>0</sharedVotingPower>
                <soleDispositivePower>3840165</soleDispositivePower>
                <sharedDispositivePower>0</sharedDispositivePower>
            </reportingPersonBeneficiallyOwnedNumberOfShares>
            <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3840165</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
            <classPercent>6.3</classPercent>
            <typeOfReportingPerson>HC</typeOfReportingPerson>
        </coverPageHeaderReportingPersonDetails>
        <items>
            <item1>
                <issuerName>Monte Rosa Therapeutics, Inc.</issuerName>
                <issuerPrincipalExecutiveOfficeAddress>321 HARRISON AVENUESUITE 900 BOSTON MA 02118</issuerPrincipalExecutiveOfficeAddress>
            </item1>
            <item2>
                <filingPersonName>BlackRock, Inc.
                In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.</filingPersonName>
                <principalBusinessOfficeOrResidenceAddress>BlackRock, Inc. 50 Hudson Yards New York, NY 10001</principalBusinessOfficeOrResidenceAddress>
                <citizenship>See Item 4 of Cover Page</citizenship>
            </item2>
            <item3>
                <notApplicableFlag>N</notApplicableFlag>
                <typeOfPersonFiling>HC</typeOfPersonFiling>
            </item3>
            <item4>
                <amountBeneficiallyOwned>3840165</amountBeneficiallyOwned>
                <classPercent>6.3</classPercent>
                <numberOfSharesPersonHas>
                    <solePowerOrDirectToVote>3782397</solePowerOrDirectToVote>
                    <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
                    <solePowerOrDirectToDispose>3840165</solePowerOrDirectToDispose>
                    <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
                </numberOfSharesPersonHas>
            </item4>
            <item5>
                  <notApplicableFlag>Y</notApplicableFlag>
                  <classOwnership5PercentOrLess>N</classOwnership5PercentOrLess>
            </item5>
            <item6>
                <notApplicableFlag>N</notApplicableFlag>
               <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Various persons have the right to receive or the power to direct
               the receipt of dividends from, or the proceeds from the sale of
               the common stock of
               Monte Rosa Therapeutics, Inc..
               No one person's interest in the common stock of
               Monte Rosa Therapeutics, Inc.
               is more than five percent of the total outstanding common shares.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>


            </item6>
            <item7>
                <notApplicableFlag>N</notApplicableFlag>
                <subsidiaryIdentificationAndClassification>See Exhibit 99</subsidiaryIdentificationAndClassification>
            </item7>
            <item8>
                <notApplicableFlag>Y</notApplicableFlag>
            </item8>
            <item9>
                <notApplicableFlag>Y</notApplicableFlag>
            </item9>
            <item10>
                <notApplicableFlag>N</notApplicableFlag>
                <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
            </item10>
        </items>
        <signatureInformation>
            <reportingPersonName>BlackRock, Inc.</reportingPersonName>
            <signatureDetails>
                <signature>Spencer Fleming</signature>
                <title>Managing Director</title>
                <date>02/04/2025</date>
            </signatureDetails>
        </signatureInformation>
    </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>PowerOfAttorney.txt
<DESCRIPTION>EXHIBIT 24: POWER OF ATTORNEY
<TEXT>
POWER OF ATTORNEY

The undersigned, BlackRock, Inc., a corporation duly organized under the
laws of the State of Delaware, United States (the "Company"), does hereby
make, constitute and appoint each of Eric Andruczyk, Richard Cundiff,
R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles,
Christopher Meade, Charles Park, James Raby, Daniel Riemer, David
Rothenberg and Brenda Schulz, acting severally, as its true and lawful
attorneys-in-fact, for the purpose of, from time to time, executing, in its
name and on its behalf and on behalf of its direct and indirect
subsidiaries and affiliates, any and all documents, certificates,
instruments, statements, filings, agreements and amendments
(collectively, "documents") determined by such person to be necessary or
appropriate to comply with ownership or control-person reporting
requirements imposed by any United States or non-United States governmental
or regulatory authority, including, without limitation, Schedules 13D and
13G and Forms 3, 4, 5, 13F, 13H, SHO and N-PX and any amendments to any of
the foregoing as may be required to be filed with the Securities and
Exchange Commission, and delivering, furnishing or filing any such
documents with the appropriate governmental or regulatory authority or
other person, and giving and granting to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any
of the rights and powers herein granted, as fully and to all intents and
purposes as the Company and/or its direct and indirect subsidiaries, as
applicable, might or could do if personally present by one of its
authorized signatories, hereby ratifying and confirming all that said
attorney-in-fact shall lawfully do or cause to be done by virtue hereof.
Any such determination by an attorney-in-fact named herein shall be
conclusively evidenced by such person's execution, delivery, furnishing or
filing of the applicable document.

This power of attorney shall expressly revoke the power of attorney dated
30th day of April, 2023 in respect of the subject matter hereof, shall
be valid from the date hereof and shall remain in full force and effect
until either revoked in writing by the Company, or, in respect of any
attorney-in-fact named herein, until such person ceases to be an employee
of the Company or one of its affiliates.

IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be
executed as of this 21st day of January, 2025.

BLACKROCK, INC.


By: /s/ R. Andrew Dickson, III
Name:  R. Andrew Dickson, III
Title: Corporate Secretary

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>ITEM7.txt
<DESCRIPTION>EXHIBIT 99: ITEM 7
<TEXT>
 Aperio Group, LLC
 BlackRock Advisors, LLC
 SpiderRock Advisors, LLC
 BlackRock Asset Management Canada Limited
 BlackRock Fund Advisors
 BlackRock Asset Management Ireland Limited
 BlackRock Institutional Trust Company, National Association
 BlackRock Financial Management, Inc.
 BlackRock Investment Management, LLC



*Entity beneficially owns 5% or greater of the outstanding
shares of the security class being reported on this
Schedule 13G.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
